Bedrijfsoverzicht
Immunome, Inc. is a biotechnology enterprise focused on the end-to-end lifecycle of antibody-drug conjugates and other therapeutics for oncology within the United States. The company operates within the healthcare sector, specifically the biotechnology industry, which typically involves high capital expenditure in research and development prior to commercial product realization. The organization employs a workforce of 177 individuals and holds a market capitalization of $2.45 billion, with trailing twelve-month revenue recorded at $6.94 million. These valuation metrics, particularly a market cap significantly exceeding annual revenue, indicate that the market is pricing the company based on future clinical potential and pipeline assets rather than current cash flow generation.
Financiële gezondheid
The company reported revenue of $6.94 million over the trailing twelve months, while posting a net income of $-212,394,000 and an EBITDA of $-211,647,008. The substantial negative net income relative to the modest revenue figure reveals a cost structure dominated by heavy research, development, and operational expenses that exceed all income sources. Free cash flow stands at $-133,619,624, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating surplus liquidity. Gross margin is 0.0%, operating margin is -3084.8%, and profit margin is 0.0%; these figures reflect a pre-revenue or early-stage commercialization phase where direct costs of goods sold and operating overheads are not yet covered by sales proceeds. The entity holds $653.48 million in cash against a debt load of $3.85 million, resulting in a debt-to-equity ratio of 0.61. Despite the negative earnings, the balance sheet is heavily conservative due to the massive cash reserve dwarfing the minimal debt obligation. The current ratio is 14.69, which signifies an exceptionally strong short-term liquidity position where current assets vastly exceed current liabilities. Return on Equity is -52.1% and Return on Assets is -29.0%, metrics that indicate management is currently utilizing the company's capital base to generate losses rather than positive returns, a common characteristic in biotechnology firms with significant pipeline investments.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -10.25, implying that expected future earnings remain negative or the market is valuing the stock on non-earnings multiples. The price-to-book ratio stands at 3.86, suggesting that the market is valuing the company at a significant premium over its tangible book value, likely reflecting the intangible value of its intellectual property and clinical pipeline. Alternative valuation metrics such as the price-to-sales ratio of 353.21 and an EV/EBITDA of -8.51 further illustrate that traditional earnings-based valuation models are not applicable, and investors are pricing the stock based on growth expectations and asset backing. The stock has traded between a 52-week high of $27.65 and a 52-week low of $6.96, indicating significant volatility and a wide trading range where the current price position fluctuates relative to this historical spectrum. The beta is 2.14, which means the stock price is expected to be 114% more volatile than the broader market, exposing investors to higher systematic risk during market downturns.
Growth & Income
Revenue growth year-over-year is -100.0%, and earnings growth year-over-year is N/A, indicating that the company has not yet achieved positive earnings or significant revenue expansion in the most recent period compared to prior reporting. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings, when positive in the future, or existing cash reserves are intended to be reinvested into growth initiatives rather than distributed to shareholders. The absence of a dividend program is consistent with the biotechnology sector's lifecycle, where capital is prioritized for clinical trials and commercialization efforts. Overall, the growth and income profile is characterized by a lack of current profitability and dividend income, relying entirely on the successful execution of its clinical assets like Varegacestat to drive future value creation.